Kolon TissueGene, Inc. announced that it has resumed patient dosing in its U.S. Phase III study of TG-C for the treatment of knee osteoarthritis (OA). The two (2) pivotal Phase III trials for U.S. approval of TG-C will enroll close to 1,020 patients at over 80 clinical sites across the U.S. During the trials, the Company will assess pain and function endpoints, as well as MRI, X-Ray, and biochemical biomarkers. In addition to significant pain and function improvements, the Company has designed the trials for TG-C to achieve a Disease Modifying Osteoarthritis Drug or "DMOAD" designation. The trial investigators will include orthopedic surgeons, rheumatologists, and pain specialists.